Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Mounjaro and Zepbound generated combined sales of $6.15 billion in the first quarter of 2025, accounting for around 48% of the company’s total revenues. Both drugs enjoy increasing market share ...

According to UBS, the company’s next major driver is the SURPASS cardiovascular outcomes trial. The bank added that Eli Lilly ...

Though sales of Mounjaro and Zepbound were below expectations in the second half of 2024, hurt by slower-than-expected growth and unfavorable channel dynamics, their sales picked up in the first ...

Last week, Australia’s Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnoea, a ...

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both have witnessed rapid demand despite being on the market for less than ...

Tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) injections were previously in shortage. The supply is beginning to stabilize, but certain doses may still be limited or sell out ...

How does it work? Published: June 12, 2025 2:47am EDT Sleep disorders Health weight-loss drugs Sleep apnea Mounjaro Tirzepatide Health in the news Register now ...